Transcept Pharmaceuticals Inc. would use some of the $37.6 million it hopes to net from a public stock offering to sell its FDA-approved middle-of-the-night sleep drug and to move forward with a drug for obsessive compulsive disorder.
Transcept priced the offering of 4.5 million shares at $9 per share.
No comments:
Post a Comment